NCT04754698View on ClinicalTrials.gov

COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS

PHASE4CompletedINTERVENTIONAL
Enrollment

2,196

Participants

Timeline

Start Date

February 9, 2021

Primary Completion Date

November 27, 2023

Study Completion Date

March 22, 2024

Conditions
Rheumatic DiseaseHIV InfectionsAIDSSafety IssuesImmunogenicityCOVID-19
Interventions
BIOLOGICAL

CoronaVac

CoronaVac (Sinovac Biotech Ltd., Beijing, China)

Trial Locations (1)

05403000

University of Sao Paulo General Hospital, São Paulo

All Listed Sponsors
lead

University of Sao Paulo General Hospital

OTHER

NCT04754698 - COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS | Biotech Hunter | Biotech Hunter